Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients

There is strong evidence that the host’s cellular immune response is linked to tumor progression, however its impact on patient outcome in breast cancer is poorly understood. The purpose of this study is to define tumor immune subtypes, focusing on cellular immune responses and investigate their prognostic effect in breast cancer patients. Our training (n = 440) and validation cohort (n = 382) consisted of all early breast cancer patients primarily treated with surgery in our center between 1985 and 1996. Tumor tissue sections were immunohistochemically stained for CD8 (CTL) and PEN5 (NK cells). Tumor expression of classical and non-classical human leukocyte antigen class I, and tumor-infiltrating Tregs were previously determined. Tumor immune subtypes were constructed based on quantification of these markers and biological rationale. High, intermediate, and low immune susceptible tumor immune subtypes were found, respectively, in 16, 63, and 20 % of patients in the training cohort and 16, 71, and 13 % in the validation cohort. The subtypes showed to be statistically significant prognostic in multivariate analyses for relapse free period (RFP) [p < 0.0001, intermediate versus high: hazard ratio (HR) 1.95; low versus high HR 2.98] and relative survival (RS) (p = 0.006, intermediate versus high HR 3.84; low versus high: HR 4.26). Validation of these outcome analyses confirmed the independent prognostic associations: RFP (p = 0.025) and RS (p = 0.040). The tumor immune subtypes that we present represent a prognostic profile with solid underlying biological rationale and with high discriminative power confirmed in an independent validation cohort. Our results emphasize the importance of tumor immune surveillance in the control of tumor development and, therefore, in determining patient prognosis. Tumor immune subtype profiling is promising for prognosis prediction and the achievement of tailored treatment for breast cancer patients.

[1]  M. Redondo,et al.  Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. , 2003, Human pathology.

[2]  R. Matkowski,et al.  The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. , 2009, Anticancer research.

[3]  H. Wiendl,et al.  Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? , 2007, Seminars in cancer biology.

[4]  L. Tryggvadottir,et al.  Altered expression of HLA class I antigens in breast cancer: Association with prognosis , 2000 .

[5]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[7]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[8]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[9]  H. Putter,et al.  Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis , 2004, Laboratory Investigation.

[10]  H. Putter,et al.  COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients , 2011, Breast Cancer Research and Treatment.

[11]  H. Putter,et al.  The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer , 2010, Clinical Cancer Research.

[12]  I. Shih,et al.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma , 2006, Virchows Archiv.

[13]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[14]  D. Geraghty,et al.  Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.

[15]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[16]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[17]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[19]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[20]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[21]  Federico Garrido,et al.  The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.

[22]  C. Lawton,et al.  Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer , 2012 .

[23]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[24]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[25]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[26]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[29]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[30]  J. Dausset,et al.  Specific activation of the non‐classical class I histocompatibility HLA‐G antigen and expression of the ILT2 inhibitory receptor in human breast cancer , 2002, The Journal of pathology.

[31]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[32]  I. Ellis,et al.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer , 2005, International journal of cancer.